Floatz logo

Dabrafenib

Precision Medicine

Tianjin Medical University Second HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Precision Medicine cohort.

Asset / SponsorPhaseRating
gw786034
Tianjin Medical University Second Hospital
Phase 2B
Palbociclib
Tianjin Medical University Second Hospital
Phase 2B
gsk1120212
Tianjin Medical University Second Hospital
Phase 2CCC
Tucidinostat
Tianjin Medical University Second Hospital
Phase 2CCC
Vebreltinib
Tianjin Medical University Second Hospital
Phase 2CCC

View all 11 →

Same molecule, other indications

Dabrafenib is also rated in:

cutaneous melanomaDormant
BB
Indicative ·
66 / 100
View asset →
melanomaDormant
BB
Indicative ·
66 / 100
View asset →
melanomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →